Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace Directory

LC-free MALDI-TOF assay for protein C inhibitor, 9/13

SISCAPA Assay Technologies (SAT) announced publication of a study in Clinical Chemistry demonstrating that one of the company’s MALDI-TOF assays for protein C inhibitor can help identify patients at risk for recurrence of prostate cancer after radiotherapy. The assay measures a proteotypic peptide of protein C inhibitor enriched from tryptic digests of patient serum by anti-peptide antibodies (the SISCAPA, or Stable Isotope Standards and Capture by Anti-Peptide Antibodies, workflow), followed by quantitation using simple MALDI-TOF mass spectrometry. A significant post-treatment

Microbial genotyping system, 9/13

Sagentia has completed initial alpha prototype development of the Resolution microbial genotyping system that it is developing for PathoGenetix. Sagentia has worked with PathoGenetix for the past two years across the full product development life cycle, helping to combine two bread board systems into an intuitive, usable system with a smaller footprint. The Resolution system is based on PathoGenetix’s Genome Sequence Scanning (GSS) technology developed to detect biothreat pathogens in environmental samples. The technology is being developed for faster and

Vitamin D IVD reagent kits, 9/13

AACC 2013 AB Sciex has introduced its Sciex IVD-MS kits, which are a new series of reagent kits for in vitro diagnostic use in conjunction with mass spectrometry instrumentation for clinical analysis in Europe. The first kit is focused on vitamin D analysis and is CE-Marked to meet European regulatory requirements. The Sciex IVD-MS kit for 25-OH vitamin D analysis is designed to help clinicians make diagnoses of vitamin D deficiencies, with the ability to quantitate 25-OH vitamin D2 and

Mass spectrometry systems, 9/13

AACC 2013 AB Sciex has launched in Europe its 3200MD CE-IVDD series, which includes the API 3200MD and 3200MD QTRAP LC/MS/MS systems. The systems are now CE-Marked. AB Sciex, 800-343-1346

Drug screening software, 9/13

AACC 2013 AB Sciex’s MPX TF 1.0 software is designed to accelerate drug screening, with accurate mass-based technology for laboratories performing clinical research. The software delivers faster turnaround times, increased sample throughput, and lower costs compared with single-stream, mass spectrometry (MS) methods. With the MPX TF software, researchers can increase throughput by as much as twofold. This is made possible by enabling the use of two parallel liquid chromatography streams. The ability to stagger chromatographic runs while collecting sample data

ELISA procedure to quantify human IgG, 9/13

The Binding Site now offers a specifically formulated and optimized ELISA procedure for the quantitation of intact human IgG from matrices containing non-human proteins. The assay is for clinical, biopharmaceutical, and medical researchers. The ELISA uses sheep polyclonal antibody, specific to the Fc and light chain regions of human IgG for capture and detection respectively, ensuring that only intact human IgG is quantified. The assay virtually eliminates any cross-reactivity to common laboratory species (for example, mouse, rat, primate) and to

TMB substrate-chromogen, 9/13

The Binding Site now offers a substrate-chromogen containing 3,3’,5,5’-tetramethylbenzidine (TMB). Designed for use as an integral component in peroxidase-based, colorimetric techniques, the TMB chromagen-substrate is for use in enzyme immunoassay test procedures. The TMB substrate-chromagen demonstrates decreased sensitivity to light when compared with other peroxidase chromogens and can be developed without any special precautions. Offered in a liquid-stable, ready-to-use format, the product displays exceptional shelf-life stability, lot-to-lot consistency, and specific performance characteristics. The TMB substrate-chromagen also permits for a safe

Human protein antibodies, 9/13

The Binding Site now offers a specialized line of anti-human serum protein antibodies. Through the use of a patented technique, which yields highly specific antibodies, all available products display a high degree of purity, shelf-life stability, and lot-to-lot consistency. The range of specialized antibodies includes those involved in blood coagulation, complement activation, acute-phase reactants, immunoglobulin response, and others. The antibodies can be conjugated to biotin, fluorescein, horseradish peroxidase, rhodamine, and others. The Binding Site, 800-633-4484

Water purification system, 9/13

Thermo Fisher Scientific has launched its Barnstead GenPure xCAD Plus water purification system, which has technology that allows simultaneous dispensing from three remote dispensers for exceptional flexibility and ease of use in shared laboratory environments. In addition to its advanced dispensing technology, the Barnstead GenPure xCAD Plus is easy to use and comes with leak detection, feed water monitoring, and all the consumables necessary to get started, allowing for simple ordering and setup. The system, now available in North America

Streamlined workflow for HPV test, 9/13

The FDA in June approved a workflow process for Roche Diagnostics’ Cobas HPV test that allows sample processing from the primary sample collection vial after it has been used for cytology (Pap) testing. The approval allows labs to load the same vial used for a ThinPrep Pap test directly onto Roche’s Cobas 4800 system for high-risk HPV and individual HPV 16 and 18 genotype testing. The new workflow option uses a special primary vial rack for the fully automated Cobas

MARKETPLACE

TRENDING